According to Stock Target Advisor, Illumina, Inc. (ILMN:NSD) has received an average “Hold” rating from the 23 research firms covering the company. Out of the total, three equity research analysts have recommended selling Illumina stock, six recommend holding, and seven recommend buying it. The brokers who issued reports on the ILMN stock in the last 12 months have an average price target of $249.37.
Illumina Stock-Analyst Ratings:
Recently, several research firms have given their opinion on the ILMN stock. Bank of America has increased the price target of Illumina from $210.00 to $230.00 in its report on February 8th.
Royal Bank of Canada has decreased the price target from $303.00 to $300.00 but maintained an “outperform” rating for the stock in a research note on Wednesday.
Canaccord Genuity Group has decreased its price target on shares of Illumina from $330.00 to $300.00 and set a “buy” rating for the company in a research note on January 17th.
On January 25th, Argus downgraded Illumina from a “buy” rating to a “hold” rating, citing the move as a valuation call.
Finally, on January 4th, Scotiabank initiated coverage on the shares of Illumina, setting a “sector perform” rating and a $216.00 target price on Illumina stock.
In other Illumina news, there have been insider transactions in the company. SVP Susan H. Tousi sold 500 shares of the firm’s stock at an average price of $204.58 on January 6th. Following the sale, the senior vice president now owns 38,662 shares of Illumina stock, valued at $7,909,471.96.
Also, SVP Aimee L. Hoyt sold 3,917 shares of Illumina stock at an average price of $199.06 on March 1st. Following the sale, the senior vice president now directly owns 2,881 shares of the ILMN stock, valued at approximately $573,491.86.
Over the last 90 days, insiders have sold 11,186 shares of the company’s stock, worth $2,255,837. Insiders own 0.13% of the Illumina stock.
Illumina Stock Price Analysis:
On Friday, the company opened at $224.95, trading down 1.4%. Illumina has a current ratio of 1.28, a quick ratio of 1.08, and a debt-to-equity ratio of 0.23.
ILMN stock has a market capitalization of $35.54 billion, a PE ratio of -8.03, and a PEG ratio. Its 50-day moving average price is $208.40, and its 200-day moving average price is $208.60. The stock’s 1-year low is $173.45, and its 1-year high is $371.16.
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments.
It markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.